Mergers & Acquisitions
Baxter and Gambro seal the deal on $3.9B acquisition
Aussie regulators approve Baxter’s $4B Gambro merger
Rochester Medical skyrockets on $262M Bard acquisition news
Advance Medical raises $20M, buys Brazilian rival and scoops execs from GE, Sanofi
Advance Medical had a big week, raising $20 million through a new equity financing round, nabbing all the assets of rival Brazilian distributor Imunotech Sistemas and adding a pair of medtech veterans to its team.
China probes medtech pricing | Wall Street Beat
The Chinese Commerce Ministry’s anti-monopoly bureau is looking for information on pricing and operations at medical device makers within the country as well as from around the world, according to a Reuters report.
Local sources told the new service that concerns about local corruption and price-fixing may have spurred the survey, but a deputy director at the China Assn. for Medial Devices Industry told reporters that there hadn’t been word of any official investigations into the sector.
LeMaitre Vascular scoops up InaVein for $2.5M
LeMaitre Vascular (NSDQ:LMAT) is jumping into the varicose vein removal business with a $2.5 million buyout of InaVein. The Burlington, Mass.-based vascular device maker snatched up InaVein for more than 100% more than the company’s 2012 sales, according to a company statement.
Medtronic hands Pioneer Plus catheters to Volcano in closed-doors deal
Abbott closes $310M IDEV Technologies buy
Baxter appeases EU regulators in $4B Gambro buyout
Medafor agrees to Bard buyout worth up to $280M
C.R. Bard (NYSE:BCR) said it agreed to pay $200 million up front and another possible $80 million for Medafor and its line of anti-bleeding agents.
Minneapolis-based Medafor makes plant-based hemostatic agents including the Arista MPH agent, which won CE Mark approval in the European Union in 2003 and garnered FDA approval for surgical use in 2006.